

# Acute Coronary Syndromes Committee meeting 7

**Date:** 27 /03/2019

**Location:** Boardroom, National Guideline Centre, Royal College of  
Physicians London

**Minutes:** Final

<b>Committee members present:</b>	
Margaret Lally (Chair)	(Present for notes 1 – 6)
Simon Corbett (Topic adviser)	(Present for notes 1 – 6)
Farrah Al-Ghita	(Present for notes 1 – 6)
Chris Cassidy	(Present for notes 1 – 6)
Ewan Gittins	(Present for notes 1 – 6)
Lance Goodman	(Present for notes 1 – 6)
Muhammad Murad Khan	(Present for notes 1 – 6)
Alun Roebuck	(Present for notes 1 – 6)
Jaydeep Sarma	(Present for notes 1 – 6)
Neil Swanson	(Present for notes 1 – 6)

<b>In attendance:</b>		
Jill Cobb	Information Specialist, NGC	(present for notes 5)
Annabelle Davies	Health Economist, NGC	(Present for notes 1 – 6)
Saoussen Ftouh	Senior Research Fellow, NGC	(Present for notes 1 – 6)
Bernard Higgins	Clinical Director and Guideline Lead, NGC	(Present for notes 1 – 6)
Sedina Lewis	Senior Research Fellow, NGC	(Present for notes 1 – 6)
Nancy Pursey	Senior Project Manager, NGC	(Present for notes 1 – 6)

<b>Apologies:</b>	
Alex Sharp	Committee member
Agnes Cuyas	Information Specialist, NGC
Kate Lovibond	Health Economics Lead, NGC

## 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 7<sup>th</sup> meeting on acute coronary syndromes (second day of a two day meeting).

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review of the evidence for culprit vessel only versus multi-vessel revascularisation
- Draft protocol for optimum duration of beta blockers following a myocardial infarction

## Introductions

## 2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was reviewing the evidence for culprit vessel only versus multi-vessel revascularisation. The Chair asked everyone to verbally declare any interests that have arisen since the last meeting and none were declared.

The chair noted that one of the studies included in the economic analysis for culprit vs. multi vessel revascularisation (Barton 2017) draws on a trial funded by the British Heart Foundation (BHF). Ewan Gittins is a member of the BHF's Patient Advisory Group. The study pre-dates Ewan's involvement with the BHF and there is no conflict of interest.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

## 4. Evidence review: culprit vessel vs multi vessel percutaneous coronary intervention (PCI)

The Chair introduced Saoussen Ftouh, Senior Research Fellow, NGC, who gave a presentation on the evidence for clinical effectiveness of multi-vessel PCI versus culprit vessel primary PCI.

The Chair introduced Annabelle Davies, Health Economist, NGC, who gave a presentation on the evidence for cost effectiveness multi-vessel PCI versus culprit vessel primary PCI.

The Committee then discussed the evidence and drafted recommendations.

**5. Draft protocol: beta-blocker duration**

The committee discussed the draft protocol for the review question: what is the optimal duration of beta-blocker therapy to improve outcomes for adults without left ventricular dysfunction after myocardial infarction?

**6. Any other business**

None

**Date of next meeting:** 30/04/2019

**Location of next meeting:** National Guideline Centre, Royal College of Physicians London